Opus Genetics (NASDAQ:IRD – Get Free Report) issued its earnings results on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93), Zacks reports. The firm had revenue of $3.40 million during the quarter, compared to the consensus estimate of $11.10 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.
Opus Genetics Price Performance
Shares of NASDAQ IRD opened at $0.98 on Tuesday. The stock has a market cap of $31.46 million, a P/E ratio of -0.90 and a beta of 0.28. The business has a 50 day simple moving average of $1.08. Opus Genetics has a twelve month low of $0.81 and a twelve month high of $1.56.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a research note on Wednesday, February 19th.
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
See Also
- Five stocks we like better than Opus Genetics
- Energy and Oil Stocks Explained
- CAVA Group Stock: Time to Take the Dip on This Investment Trip?
- Why Are Stock Sectors Important to Successful Investing?
- From Trading to Checking Accounts: Robinhood’s Big Bet on Banking
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 5 Hot Stock Buys for Investors in April
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
